TG THERAPEUTICS INC (NASDAQ:TGTX) has been identified as a high-growth momentum stock with a favorable technical setup. The company, focused on treatments for B-cell malignancies and autoimmune diseases, demonstrates strong earnings momentum alongside a bullish chart pattern. Below, we examine why TGTX stands out for growth investors and technical traders.
Growth Momentum Highlights
Earnings Growth: TGTX reported a 142.9% year-over-year EPS growth in the most recent quarter, following an even stronger 250% growth in the prior quarter.
Revenue Expansion: Sales grew by 90.4% quarter-over-quarter, with a trailing twelve-month revenue increase of 33.5%.
Profit Margins: The company has shown improving profitability, with a quarterly profit margin of 4.19%, up from negative figures in previous years.
Analyst Revisions: While EPS estimates for next year have seen downward revisions, revenue estimates have been revised upward by 4.8% over the past three months.
Earnings Surprises: TGTX has beaten revenue estimates in all of the last four quarters, with an average EPS beat of 36.4%.
Technical Strength & Setup
TGTX holds a Technical Rating of 9/10, reflecting strong price momentum and trend health. Key observations from the technical report include:
Uptrend Confirmation: Both short-term and long-term trends are positive, with the stock outperforming 90% of the market over the past year.
Consolidation Pattern: The stock has been trading in a range between $34.03 and $39.64 over the past month, forming a base near the upper end of this range.
Support & Resistance: Key support lies at $36.82-$37.64, while resistance is seen at $40.07. A breakout above $40 could signal further upside.
Setup Quality: With a Setup Rating of 8/10, TGTX presents a favorable risk-reward opportunity, with a suggested entry at $40.08 and a stop-loss at $36.81.
Why This Combination Matters
High-growth momentum stocks with strong technical setups often attract institutional interest, as they combine accelerating fundamentals with favorable price action. TGTX fits this profile, making it a candidate for investors following CANSLIM or Minervini-style strategies.